Rewarding Results: Moving Forward on Value-Based Contracting for Biopharmaceuticals

Posted On March 23rd, 2017

Rewarding Results: Moving Forward on Value-Based Contracting  for Biopharmaceuticals
NEHI's findings on one promising approach to managing biopharmaceutical costs

The shift under way in payment in US health care - from volume to value - has sparked interest in new contracting arrangements to pay for prescription drugs. The objective of these new arrangements is to reward successful outcomes of medication use in patients, rather than pay based on the volume of drugs sold. These value-based contracts represent one approach to managing drug costs and obtaining better value for money spent. However, achieving the full potential of these contracts will necessitate regulatory and other changes.

NEHI's white paper outlines the opportunities for, and obstacles to, value-based contracting, and provides reccomendations for moving foward. 

View more publications

NEHI Member Spotlight

See our full member directory

Back to Top